Cited by 41Diabetes Treatment and ManagementRegulation of Appetite and ObesityPharmacology and Obesity Treatment

Enteroendocrine hormone mimetics for the treatment of obesity and diabetes

Irwin, Nigel, Flatt, Peter R·2013·Current Opinion in Pharmacology

Abstract

The utilisation of gastrointestinal-derived hormones as treatment options for obesity-diabetes has been well publicised. This has been fuelled by the synthesis of longer-acting peptide forms and beneficial altered secretion of gut hormones following certain gastric bypass surgeries. The aim of this review is to highlight the potential of glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), cholecystokinin (CCK) and oxyntomodulin (OXM) as treatments for obesity-diabetes. To date, long-acting GLP-1 receptor mimetics have achieved clinical utility for diabetes. GIP, CCK and OXM molecules appear to offer promising new classes of drugs. Furthermore, recent observations suggest significant potential for concurrent modulation of numerous receptor sub-families in the treatment of obesity-diabetes. Thus, gut hormones offer an expanding family of druggable targets for obesity-diabetes.

Integrity signals

Registry

Crossref · 10.1016/j.coph.2013.09.009

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Irwin, N., & Flatt, P. R.
Affiliations
University of Ulster (GB)
Corresponding author
Irwin, Nigel
Venue
Current Opinion in Pharmacology
Publisher
Elsevier BV
Published
2013-12
Volume
13
Issue
6
Pages
989-995
ISSN
1471-4892 (ISSN-L)
OpenAlex
W1993607264
Cited by
41
References
9
Citations by year
2024: 1 · 2023: 1 · 2022: 2 · 2021: 4 · 2020: 1 · 2019: 4 · 2018: 6 · 2017: 2 · 2016: 5 · 2015: 5 · 2014: 10
FWCI
0.97
Type
journal article
Language
en
Open access
closed
Locations
  • Current Opinion in Pharmacology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
  • Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
Keywords
enteroendocrine hormones, gastrointestinal hormones, obesity, diabetes mellitus, glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, cholecystokinin, oxyntomodulin, GLP-1 receptor agonists, gastric bypass, receptor modulation, druggable targets
MeSH terms
Glucagon-Like Peptide-1 Receptor, Animals, Diabetes Mellitus, Gastrointestinal Hormones, Humans, Obesity, Receptors, Glucagon, Enteroendocrine Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review